SANION Stock Overview
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.83 |
| 52 Week High | kr12.44 |
| 52 Week Low | kr1.77 |
| Beta | 1 |
| 1 Month Change | -3.39% |
| 3 Month Change | -30.57% |
| 1 Year Change | -76.44% |
| 3 Year Change | -92.61% |
| 5 Year Change | -93.04% |
| Change since IPO | -64.54% |
Recent News & Updates
Recent updates
Saniona (STO:SANION) Is Making Moderate Use Of Debt
Nov 29
Is Saniona (STO:SANION) Using Too Much Debt?
Aug 16Is Saniona (STO:SANION) Using Too Much Debt?
Mar 17Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares
Feb 10What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?
Jan 06Is Saniona (STO:SANION) Using Too Much Debt?
Dec 02Shareholder Returns
| SANION | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.8% | -1.0% | -1.7% |
| 1Y | -76.4% | -6.3% | 8.1% |
Return vs Industry: SANION underperformed the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: SANION underperformed the Swedish Market which returned 8.8% over the past year.
Price Volatility
| SANION volatility | |
|---|---|
| SANION Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: SANION's share price has been volatile over the past 3 months.
Volatility Over Time: SANION's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Denmark. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity.
Saniona AB (publ) Fundamentals Summary
| SANION fundamental statistics | |
|---|---|
| Market cap | kr203.12m |
| Earnings (TTM) | -kr95.81m |
| Revenue (TTM) | kr16.84m |
12.1x
P/S Ratio-2.1x
P/E RatioIs SANION overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANION income statement (TTM) | |
|---|---|
| Revenue | kr16.84m |
| Cost of Revenue | kr5.06m |
| Gross Profit | kr11.78m |
| Other Expenses | kr107.59m |
| Earnings | -kr95.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 69.96% |
| Net Profit Margin | -568.94% |
| Debt/Equity Ratio | -297.3% |
How did SANION perform over the long term?
See historical performance and comparison